Michael Palumbo, MD
Allergy · Pittsburgh, PANPI 1083662720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $460,763 of the $561,444 with a category attached, or 82.1%. 40 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. 2025 is the largest year on record at $158,263, 2.1 times the $76,251 reported in 2019. Among allergy clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,109 payments — averaging $506.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$144K
- CSL Behring$118K
- Regeneron Healthcare Solutions, Inc.$91K
- Sanofi$80K
- Grifols USA, LLC$48K
- Novartis$18K
- plus $63K from 34 others
Across 463 payments — averaging $8425.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$960K
- Eli Lilly$715K
- GSK$371K
- Sanofi$334K
- Genentech, Inc.$226K
- Grifols Therapeutics LLC$203K
- plus $1.1M from 13 others
What the payments were for
- Consulting fees$40,1337%
- Speaking & faculty fees$460,76382%
- Travel & lodging$35,9056%
- Food & beverage$24,6324%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$561,444 in reported general payments places this provider in the 95th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 11 | $90,463 |
| XolairOmalizumab | 17 | $75,832 |
| Fasenra PenBenralizumab | 13 | $74,197 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $74,189 |
| RinvoqUpadacitinib | 12 | $73,202 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $55,873 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $17,002 |
| Arnuity ElliptaFluticasone Furoate | 46 | $15,459 |
| Cromolyn Sodium | 13 | $15,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,812 |
| Qvar RedihalerBeclomethasone Dipropionate | 18 | $9,807 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,411 |
| Ipratropium Bromide | 152 | $5,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $3,940 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $3,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $3,858 | $90,46311 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,234 | $88,334130 claims |
| Grifols USA, LLCXembify | $47,547 | $74,18913 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $143,555 | $19,22428 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $22 | $15,32413 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $10,106 | $9,80718 claims |
| Hikma Pharmaceuticals USAEpinephrine | $6,495 | $3,65115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Pittsburgh
- James DeangeloPittsburgh$79K
- David MillerPittsburgh$7K
- Allyson LarkinPittsburgh$1K
- Richard GreenPittsburgh$139
- Andrew VayonisPittsburgh$15
- Shannon KearneyBethlehem$48K
- Rehan MujahidWind Gap$16K
- Schweta ArakaliAllentown$12K
- Michelle WeissYork$7K
- Andrew MurphyWest Chester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.